Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Nov. 10 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended September 30, 2008.

"The third quarter represented another quarter of significant achievement and progress and was capped with the signing of our partnering agreement with Pfizer for Dimebon. This collaboration not only gives us access to a world-class partner capable of maximizing global commercialization, but also provides significant funding allowing us to invest in all of our clinical programs and actively pursue other drug candidates," said David Hung, M.D., president and chief executive officer of Medivation. "We are working with Pfizer on an extensive program to support a broad label for Dimebon in Alzheimer's disease beyond our original plan to pursue the treatment of mild-to-moderate Alzheimer's, and to achieve comprehensive and expeditious regulatory submissions and market acceptance. Accordingly, together we intend to expand development of Dimebon to include new Phase 3 trials in addition to the CONNECTION study. We expect to begin the new trials in 2009 and to file a New Drug Application (NDA) for a broader Alzheimer's disease label in 2011."

Corporate Update

Dimebon: Drug candidate to treat Alzheimer's and Huntington's diseases

-- Entered into an agreement with Pfizer Inc. to jointly develop and

commercialize Dimebon for the treatment of Alzheimer's and Huntington's

diseases. Under the terms of the agreement, Medivation has received an

up-front cash payment of $225 million and is eligible to receive

payments of up to $500 mill
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions driven ... record-breaking year across the board for the company. , ... and our Smart Data solutions, our customers were able to ... to record growth for the company in 2014,” said Alok ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
(Date:12/25/2014)... December 25, 2014 The report “Service ... Product Type & Provider Type - Global Advancements, Worldwide ... with an in-depth analysis and forecasting of revenues. ... through 221 pages and in-depth TOC on “Service Quality ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... - New findings from the pivotal TEMSO Phase III study presented ... - U.S. FDA Accepts New Drug Application for   ... (EURONEXT: SAN and NYSE: SNY ) and its subsidiary Genzyme ... ultiple S clerosis O ral (TEMSO) Phase III trial showing ...
... scientists at the University of California at Berkeley ... viruses called M13 phages to serve as structural ... of properties. By controlling the physical environment ... into hierarchically organized thin-film structures, with complexity that ...
... Fla., Oct. 19, 2011 Physicians and scientists ... just released the results of their groundbreaking research ... Impairs Embryonic Reproductive Potential While Blastocyst Biopsy Does ... and Non-Biopsied Sibling Embryos.   The study, led ...
Cached Biology Technology:Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 2Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 3Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 4Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 5Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 6Manufacturing goes viral 2Manufacturing goes viral 3Manufacturing goes viral 4Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... to the U.S. Food and Drug Administration,s (FDA) invitation ... Draft Guidance on mobile medical applications, AMIAthe association for ... oversight of clinical decision support systems. The critical factor, ... types of software that provide clinical decision support (CDS) ...
... 14, 2011 As the United States nears another ... (BGU) have determined scientifically, for the first time, that ... According to Prof. Hagit Cohen from the Anxiety ... Sciences, "We understand that emotional changes are related and ...
... sea turtles accidentally caught and killed in fishing gear in ... percent since 1990, according to a new study by researchers ... report, published in the scientific journal Biological Conservation , ... into place over the last 20 years to reduce bycatch ...
Cached Biology News:AMIA advises FDA on clinical decision support 2Voting causes stress according to Ben-Gurion University of the Negev study 2Accidental sea turtle deaths drop 90 percent in US fisheries 2Accidental sea turtle deaths drop 90 percent in US fisheries 3